Related Experiment Video
Updated: Jan 13, 2026
11:20
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
Published on: May 7, 2018
12.6K
Unlocking Neuroprotection: Potassium Channel Openers in Alzheimer's Disease
Sarvesh Kumar1, Anjana Sharma2, Gulpreet Mehra1
1Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Sector 125, Noida, Uttar Pradesh, 201301, India.
Current Alzheimer Research
|January 8, 2026
Summary
ATP-sensitive potassium channel openers show promise for Alzheimer's disease by limiting neuronal excitability and reducing inflammation. These compounds may offer neuroprotection against key disease mechanisms.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder impacting memory and cognition.
- AD pathology involves neuroinflammation, neurodegeneration, and the buildup of amyloid plaques and neurofibrillary tangles.
- Current AD treatments offer symptomatic relief but do not address underlying pathology, necessitating novel therapeutic strategies.
Purpose of the Study:
- To explore the potential of ATP-sensitive potassium channel openers as a therapeutic approach for Alzheimer's disease.
- To investigate the cellular mechanisms by which these compounds may prevent neurodegeneration and protect neurons.
Main Methods:
- Review of cellular mechanisms of ATP-sensitive potassium channel openers relevant to AD.
- Analysis of their effects on neuronal excitability, neurotransmitter release, protein aggregation, calcium influx, oxidative stress, and microglial activation.
Main Results:
- ATP-sensitive potassium channel openers demonstrate multifaceted neuroprotective effects.
- Mechanisms include limiting neuronal excitability, modulating neurotransmitter release, preventing protein buildup, reducing calcium influx, and decreasing oxidative stress and microglial activation.
Conclusions:
- ATP-sensitive potassium channel openers represent a promising class of therapeutics for Alzheimer's disease.
- Their diverse cellular actions offer potential for both prevention and neuroprotection, targeting key pathological pathways in AD.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
624
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
624
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
01:22Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
01:19Ligand-gated Ion Channels
13.9K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
13.9K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
544
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K